451 related articles for article (PubMed ID: 24972933)
1. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
2. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
Lorkova L; Scigelova M; Arrey TN; Vit O; Pospisilova J; Doktorova E; Klanova M; Alam M; Vockova P; Maswabi B; Klener P; Petrak J
PLoS One; 2015; 10(8):e0135314. PubMed ID: 26285204
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
4. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
[TBL] [Abstract][Full Text] [Related]
5. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
Schirmer M; Stegmann AP; Geisen F; Konwalinka G
Exp Hematol; 1998 Dec; 26(13):1223-8. PubMed ID: 9845378
[TBL] [Abstract][Full Text] [Related]
6. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Hapke DM; Stegmann AP; Mitchell BS
Cancer Res; 1996 May; 56(10):2343-7. PubMed ID: 8625309
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
9. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma.
Pola R; Pokorná E; Vočková P; Böhmová E; Pechar M; Karolová J; Pankrác J; Šefc L; Helman K; Trněný M; Etrych T; Klener P
Acta Biomater; 2021 Jan; 119():349-359. PubMed ID: 33186784
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Rolland D; Raharijaona M; Barbarat A; Houlgatte R; Thieblemont C
Anticancer Res; 2010 Oct; 30(10):3951-7. PubMed ID: 21036708
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Hubeek I; Peters GJ; Broekhuizen AJ; Kaspers GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1513-6. PubMed ID: 15571288
[TBL] [Abstract][Full Text] [Related]
14. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Dumontet C; Fabianowska-Majewska K; Mantincic D; Callet Bauchu E; Tigaud I; Gandhi V; Lepoivre M; Peters GJ; Rolland MO; Wyczechowska D; Fang X; Gazzo S; Voorn DA; Vanier-Viornery A; MacKey J
Br J Haematol; 1999 Jul; 106(1):78-85. PubMed ID: 10444166
[TBL] [Abstract][Full Text] [Related]
15. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
[TBL] [Abstract][Full Text] [Related]
16. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
17. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells.
Sarkar M; Han T; Damaraju V; Carpenter P; Cass CE; Agarwal RP
Biochem Pharmacol; 2005 Aug; 70(3):426-32. PubMed ID: 15950950
[TBL] [Abstract][Full Text] [Related]
18. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Löfgren C; Albertioni F; Paul C
Ther Drug Monit; 2005 Oct; 27(5):641-6. PubMed ID: 16175139
[TBL] [Abstract][Full Text] [Related]
19. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
[TBL] [Abstract][Full Text] [Related]
20. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
